Berberine phytosome: better absorption, but also stronger effects?

Berberine phytosome pairs the plant compound berberine with phospholipids to improve its absorption. Small pharmacokinetic studies report higher blood levels than with ordinary berberine. That is an interesting step forward in formulation, but it does not yet show that diabetes, high blood lipids or body weight respond more strongly as a result. Answering those questions takes studies that measure the relevant health outcomes.

Berberine phytosome at a glance

Berberine is an isoquinoline alkaloid found in several plants, including Berberis species, Coptis chinensis and Hydrastis canadensis. The phytosome technology is sold under trade names including Berbevis. It binds berberine to phosphatidylcholine. In certain products, 500 to 550 mg of the whole complex corresponds to roughly 100 mg of berberine. The total weight on the label is therefore not the same as the amount of active ingredient.

Studies of ordinary berberine hydrochloride have often used 500 to 1,500 mg a day. These amounts cannot be transferred directly to a phytosome complex. The source article on berberine dosing covers the ordinary form; the study amounts it mentions are not a personal prescription either.

How the complex is built

A phytosome is a non-covalently bound complex of a plant compound and phosphatidylcholine, often in a molar ratio of 1:1 or 1:2. The exact composition depends on the formulation. The phospholipid is meant to ease contact with biological membranes and so make absorption easier.

Berberine carries a permanent positive charge, which limits how easily it passes through the gut wall on its own. Preclinical work on berberine-phospholipid complexes addresses this hurdle. Micelle formulations sometimes take other routes, for example through transport proteins such as P-glycoprotein. Results from these different formulations should therefore not be lumped together freely.

From plant extracts to formulation technology

Indena has developed phytosome technology since the 1980s and 1990s for plant compounds that are poorly absorbed, first for silymarin among others and later for further extracts. Berberine is a more recent application of the approach.

The plant compound itself has a long history in traditional systems of medicine. Modern research focuses in particular on its metabolic effects. The study on AMPK activation is one of the mechanistic foundations. The formulation question comes next: does changing how berberine is delivered create a practical advantage?

Mechanisms and absorption

The phytosome form still contains berberine. It changes how berberine is delivered and possibly how its concentrations rise and fall in the body, not what the active ingredient is. That does not mean, however, that all of its effects and risks can be predicted by a simple conversion.

Berberine’s metabolic pathways

AMPK helps cells regulate their energy supply. Activating it can influence glucose uptake and fatty acid processing, among other things. Animal experiments have also looked at reduced glucose production in the liver. Other work examines inflammatory signaling pathways.

These processes explain part of the research interest. Berberine is not a GLP-1 receptor agonist, though, and it is not an interchangeable herbal substitute for semaglutide. Calling it a “natural Ozempic” boils different active ingredients and clinical data down to a misleading promise.

How absorption changes

Only a small share of ordinary berberine reaches the bloodstream unchanged; commonly cited estimates are around one percent. Gut metabolism, transport mechanisms and processing in the liver all contribute. The exact figure depends on the study model and does not capture every possible effect inside the gut.

A human study of an improved formulation reported markedly higher berberine concentrations. Exposures roughly five to ten times higher are often quoted. Figures like these have to be read together with the dose, the comparison form and the parameter measured. A small crossover study of dihydroberberine looks at yet another form and is not direct proof that a phytosome is superior.

What the clinical evidence shows

Higher blood levels than ordinary berberine

This is where the most direct evidence for the formulation lies: under the conditions studied, more berberine reached the blood. That could be useful for developing lower-dose products. Whether a given amount delivers greater clinical benefit as a result is a question for separate comparison studies.

Blood sugar and metabolism

Systematic reviews report favorable changes in certain glucose and insulin measures with berberine. These include a meta-analysis on metabolic disorders and an umbrella review. Study quality, composition, populations and concurrent treatment vary. The data on berberine as a whole are more extensive than those on the phytosome form alone.

A possible improvement in HbA1c or fasting glucose is clinically interesting. It still does not make berberine a substitute for coordinated diabetes care. Nor does better absorption prove that the phytosome form improves the long-term course of the disease more.

Blood lipids in combination products

Studies of artichoke and Berberis extracts, along with research on other blended products, report changes in blood lipids. An analysis of Armolipid Plus and a further randomized trial each concern a specific combination.

When a product contains several active ingredients, the observed effect cannot be credited to berberine or its phytosome form alone. The result applies, first of all, to the whole product that was tested.

Tolerability compared

Less unabsorbed berberine in the gut could, in theory, improve tolerability. Ordinary berberine can cause diarrhea, constipation, nausea or abdominal cramps. A plausible explanation is no substitute for a sufficiently large head-to-head comparison at equal clinical effect, however. Whether the phytosome is generally easier on the stomach and gut remains an open question.

These data also offer no basis for promising meaningful weight loss in healthy adults or a cure for type 2 diabetes. For now, the strongest positive finding remains the improved absorption.

Ordinary berberine, phytosome and dihydroberberine

Berberine hydrochloride is commonly sold in capsules of about 500 mg. Some raw materials are standardized to 97 to 98 percent berberine hydrochloride. Most of the clinical research covers this form; product quality and an exact statement of the active ingredient still matter.

Berberine phytosome also contains phospholipid components. In one specific product, about 550 mg of complex can deliver around 100 mg of berberine. A certificate of analysis should therefore state both the formulation and the actual amount of berberine.

Dihydroberberine is a reduced form that also arises when berberine is processed in the gut. Products often contain about 100 to 200 mg per capsule. The clinical and long-term safety data are thinner, even if early absorption studies are interesting.

For every variant, batch-level testing for active ingredient content and contaminants is helpful. Independent testing programs can supply information, but a given seal has to apply to the specific product and to what was actually tested. For phytosomes, a clear label includes the phosphatidylcholine source, purity and berberine content.

Regulatory context

The underlying overview describes the US supplement market as of May 2026. Marketing a product as a dietary supplement is different from approval as a medicine to treat a disease. A brand name or a licensed technology does not create a medical approval of its own.

For Germany and other countries, whether a product may be sold and which advertising claims are allowed has to be checked separately. Nor can blanket current clearance for competitive sport be inferred from the formulation. Athletes need a check of the rules that apply and of the specific product. These regulatory details have not been independently updated for this draft.

Safety, side effects and interactions

Possible complaints

Diarrhea, constipation, abdominal cramps and nausea are part of the described side effect profile. Larger amounts can make tolerability worse; 1,500 mg is not a fixed threshold below which complaints are ruled out. Headache, dizziness and changes in blood pressure have also been described. Better absorption can change exposure, which is not purely an advantage.

Drug interactions

A human study describes inhibition of certain cytochrome P450 enzymes after repeated intake. That can matter for medicines processed by these enzymes, for example some statins, immunosuppressants or calcium channel blockers. The specific substance is what counts; not every drug in a class is affected in the same way.

With insulin and sulfonylureas, an additional blood sugar-lowering effect can become relevant. With warfarin and other anticoagulants, possible interactions should be checked as well. INR monitoring applies to warfarin treatment and is not a general test of effect for direct oral anticoagulants. Combinations with other supplements that affect blood sugar also belong on the medication list.

Pregnancy, breastfeeding and organ disease

Berberine should not be used on your own initiative during pregnancy or breastfeeding. Among other concerns, there are worries about bilirubin binding and possible risks to newborns. Well-established supplement doses for children are lacking. With significant liver or kidney disease, metabolism, interactions and the lack of safety data matter especially.

When to talk to a doctor before trying it

This applies especially to pregnancy and breastfeeding, children, significant liver or kidney disease, and people taking insulin, sulfonylureas, anticoagulants, immunosuppressants or other medicines that might be affected. A complete medication list helps more than a general assurance that a plant origin makes the product well tolerated.

Comparing the forms in practice

Ordinary berberine has the larger body of studies on metabolic endpoints going for it. Phytosome products offer interesting absorption data, often cost more and leave open questions about clinical superiority. Dihydroberberine rests on a smaller evidence base.

Studies and product concepts feature roughly 500 to 1,500 mg of ordinary berberine a day, 550 mg of phytosome complex once or twice daily, or about 100 to 200 mg of dihydroberberine. These figures are not interchangeable doses and not a personal dosing plan. An accurate price comparison also has to account for the amount of active ingredient, duration and product quality.

Which values can help before and after a trial

In a medically supervised trial, the goal should be set in advance. HbA1c reflects longer-term glucose control, so a check after about twelve weeks can make sense. Fasting glucose responds over a shorter time. Insulin and derived measures such as HOMA-IR can add to specific questions, but they are not a routine panel everyone needs.

LDL cholesterol and ApoB answer questions about blood lipids and atherogenic particles. ALT and AST can be part of a liver assessment when there is reason for one. Comparable blood-draw conditions make results easier to interpret. Even a change after starting, though, does not by itself prove that the product worked: diet, exercise, medication and natural fluctuation also play a part.

The line between supplement and treatment

Intense thirst, frequent urination, unexplained weight changes or persistent fatigue should be assessed by a doctor. The symptoms determine which tests are needed. A new supplement should not delay that assessment.

If diabetes or elevated cardiovascular risk is already known, the goal remains effective overall treatment. Formulation technology may be a research question within that; it replaces neither diagnosis nor proven therapy.

Frequently asked questions

What is berberine phytosome?

A complex of berberine and phosphatidylcholine designed to change absorption. Small studies report higher blood levels. Whether that translates into greater health benefits is less clear.

What does it do in the body?

Berberine influences energy-related metabolic pathways such as AMPK, among others. The phytosome technique mainly concerns delivery. Berberine is not a GLP-1 receptor agonist.

What is it being studied for?

Mainly absorption, glucose and blood lipid values. Many clinical results come from combination products or from studies of ordinary berberine.

Is it a vitamin or mineral?

No. Berberine is a plant alkaloid; the phytosome is a formulation of this compound with phospholipids.

Where does it come from?

Berberine is obtained from plant extracts and bound to phosphatidylcholine by a manufacturing process. Indena developed a phytosome technology for this; Berbevis is an associated trade name.

How does it differ from ordinary berberine?

Blood concentrations can be higher, while each capsule contains less actual berberine. The total weight of the complex therefore cannot be compared directly with berberine hydrochloride.

Does it actually work?

Better absorption is a credible finding. For any added benefit on blood sugar or blood lipids, the phytosome-specific data are more limited. A personal decision should weigh the goal, other medications and the remaining uncertainty.

Is it sold as a dietary supplement?

Such products are sold on the supplement market. That is not approval as a medicine. The current legal status and quality have to be checked for the specific product and country.

Sources from the original material

The following references were taken over from the source material and have not been fully and independently checked for this draft.

• Yu F, Li Y, Chen Q, He Y, Wang H, Yang L, Guo S, Meng Z, Cui J, Xue M, Chen XD (2016). Monodisperse microparticles loaded with the self-assembled berberine-phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 103, 136-148. https://doi.org/10.1016/j.ejpb.2016.03.019 Source
• Kwon M, Lim DY, Lee CH, Jeon JH, Choi MK, Song IS (2020). Enhanced Intestinal Absorption and Pharmacokinetic Modulation of Berberine and Its Metabolites through the Inhibition of P-Glycoprotein and Intestinal Metabolism in Rats Using a Berberine Mixed Micelle Formulation. Pharmaceutics, 12(9). https://doi.org/10.3390/pharmaceutics12090882 Source
• Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55(8), 2256-64. https://doi.org/10.2337/db06-0006 Source
• Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, Yang D, Liang H, Ye J, Weng J (2011). Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PloS one, 6(2), e16556. https://doi.org/10.1371/journal.pone.0016556 Source
• Wang K, Yin J, Chen J, Ma J, Si H, Xia D (2024). Inhibition of inflammation by berberine: Molecular mechanism and network pharmacology analysis. Phytomedicine : international journal of phytotherapy and phytopharmacology, 128, 155258. https://doi.org/10.1016/j.phymed.2023.155258 Source
• Petrangolini G, Corti F, Ronchi M, Arnoldi L, Allegrini P, Riva A (2021). Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption: In Vitro Evidence Confirmed by Healthy Human Volunteers Pharmacokinetic Study. Evidence-based complementary and alternative medicine : eCAM, 2021, 7563889. https://doi.org/10.1155/2021/7563889 Source
• Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM (2021). Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients, 14(1). https://doi.org/10.3390/nu14010124 Source
• Zhao JV, Huang X, Zhang J, Chan YH, Tse HF, Blais JE (2023). Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Journal of nutrition, 153(10), 2939-2950. https://doi.org/10.1016/j.tjnut.2023.08.016 Source
• Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q (2021). Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in pharmacology, 12, 653887. https://doi.org/10.3389/fphar.2021.653887 Source
• Li Z, Wang Y, Xu Q, Ma J, Li X, Yan J, Tian Y, Wen Y, Chen T (2023). Berberine and health outcomes: An umbrella review. Phytotherapy research : PTR, 37(5), 2051-2066. https://doi.org/10.1002/ptr.7806 Source
• Cicero AFG, Fogacci F, Bove M, Giovannini M, Veronesi M, Borghi C (2019). Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease. The American journal of cardiology, 123(4), 588-591. https://doi.org/10.1016/j.amjcard.2018.11.018 Source
• Cicero AFG, Kennedy C, Knežević T, Bove M, Georges CMG, Šatrauskienė A, Toth PP, Fogacci F (2021). Efficacy and Safety of Armolipid Plus. Nutrients, 13(2). https://doi.org/10.3390/nu13020638 Source
• Fogacci F, Giovannini M, D’Addato S, Grandi E, Cicero AFG (2023). Effect of dietary supplementation with a new nutraceutical formulation on cardiometabolic risk factors: a double-blind, placebo-controlled, randomized clinical study. Archives of medical sciences. Atherosclerotic diseases, 8, e53-e59. https://doi.org/10.5114/amsad/166571 Source
• Imenshahidi M, Hosseinzadeh H (2019). Berberine and barberry (Berberis vulgaris): A clinical review. Phytotherapy research : PTR, 33(3), 504-523. https://doi.org/10.1002/ptr.6252 Source
• Guo Y, Chen Y, Tan, Z.-R., Klaassen CD, Zhou, H.-H. (2012). Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology, 68(2), 213–217. https://doi.org/10.1007/s00228-011-1108-2 Source